Concomitant with its proprietary program activities, Pieris intends to establish a broad footprint for the Anticalin technology by collaborating with a select group of partners to realize the therapeutic opportunities that Anticalins offer. Pieris will sign corporate partnerships in two major categories: de novo drug discovery collaborations and licensing agreements for its proprietary Anticalin programs. Based on its flexible partnering mentality and its unique proprietary position, Pieris has positioned itself as an ideal partner for companies seeking to commercialize the next generation of targeted protein therapeutics.
Pieris and its Anticalin technology have reached an exciting stage of development: the company has the ability to undertake far-reaching discovery collaborations that fully utilize the Anticalin platform's power to create an array of novel targeted protein therapeutics against virtually any type of target. Anticalins offer several key advantages over current targeted approaches, including the ability to specifically bind an increased range of therapeutic targets, particularly hapten-like targets, but also larger targets with high affinity; flexibility of formatting and convenient drug delivery formulations; cost-effective and consistent production methods; and an inherently positive safety and tolerability profile.